

20 Novembre 2019, Ore 14

Dr.ssa Donatella Romaniello Weizmann Institute of Science

Monoclonal Antibodies For Lung Cancer Therapy: strategies to bypass drug resistance.

BIOSCKETCH DR.SSA ROMANIELLO

Certified as pharmacist, Dr. Donatella Romaniello obtained her PhD in Biochemistry at University of Rome "La Sapienza". As part of her studies, she spent one year at the Memorial Sloan-Kettering Cancer Center, NEW YORK (NY). Since 2016 she has been a postdoctoral fellow in Yosef Yarden's group at the Weizmann Institute of Science, in Israel, investigating drug response and mechanisms of resistance in Non-Small Cell Lung Cancer (NSCLC) harboring EGFR mutation. Her work is focused on the effects of combining monoclonal antibodies and tyrosine kinase inhibitors as a possible strategy to bypass tumor relapses which inevitably occur in patients treated with standard therapy.